Advertorial

Dolomite Bio introduces the Nadia product family for single cell research

6
SHARES

Posted: 9 November 2017 | | No comments yet

Dolomite Bio is delighted to announce the launch of the game-changing Nadia single cell platform, a groundbreaking system set to escalate scRNA-Seq to new heights, offering the fast-growing single cell research sector an innovative solution for a wide range of potential applications…

This novel product family will be on display from the 9th to the 10th of November 2017 at the 5th Annual Single Cell Analysis Congress (Booth 14) in London, UK, at Oz Single Cells 2017 in Melbourne, Australia, and at the 3rd Annual Boston Understand Your Genome® (UYG) Conference in Cambridge, USA,  on the 14th of the month.

 

SECURE YOUR FREE SPOT

 


This webinar explores how the pharmaceutical industry can move towards sustainable autonomous operations.

Realising autonomous pharmaceutical operations | 9 February 2026 | 10am

What you’ll discover:

  • Understand the key drivers of the pharmaceutical industry and how autonomous operations are shaping its future and driving IT-OT conversion
  • Explore the value of automation in enhancing operational efficiency and driving business growth for life sciences
  • Gain expert insight on the potential benefits of implementing automation solutions.

Register now – it’s free

The Nadia instrument is a touchscreen-controlled, droplet-based microfluidic platform for single cell research, combining superior microfluidics, automated temperature control and gentle cell/bead agitation to offer a single compact instrument that delivers highly precise and reliable results. One, two, four or eight samples can be run in parallel, generating up to 6,000 high quality, single cell libraries per sample in approximately 15 minutes. Configuration with the Nadia Innovate protocol development platform transforms the system into a scalable, open system for the creation of new procedures and applications. Users can alter parameters – such as droplet size and frequency, temperature, agitation and timings – and optimise protocols with the aid of real-time visualisation, enabling straightforward development of new single cell protocols and applications.

Mike Hawes, CEO of Dolomite Bio, commented:

“We are excited to be launching the Nadia product family at conferences across three continents. This novel system represents a huge leap forward for single cell research, and we look forward to showcasing its capabilities.”

For more information, visit www.dolomite-bio.com/product/nadia-instrument/

Share via
Share via